Sentiment-Signal
16,7
Stark Bearisch
Composite Score (0–100)
Insider (25%)
0
Keine Insider-Käufe
Institutionell (22,5%)
0
Keine neuen Positionen
Aktivist (12,5%)
0
Kein 13D/13G
Risikofreier Zins (T-Bills): 3,70% (Stand: 31.03.2026)
Score-Verlauf (90 Tage)
Stammdaten
Dyne Therapeutics, Inc., a muscle disease company, operates as a biotechnology company that focuses on advancing therapeutics for genetically driven muscle diseases in the United States. It develops various programs for myotonic dystrophy type 1, duchenne muscular dystrophy, and facioscapulohumeral dystrophy, as well as rare skeletal muscle, and cardiac and metabolic muscle diseases using its FORCE platform that delivers disease-modifying therapeutics. The company was incorporated in 2017 and is headquartered in Waltham, Massachusetts..
Unternehmen & Branche
| Name | Dyne Therapeutics, Inc. |
|---|---|
| Ticker | DYN |
| CIK | 0001818794 |
| Boerse | US |
| Sektor | Healthcare |
| Industrie | Biotechnology |
| SIC | 2834 · Pharmaceutical Preparations |
Wertpapier & Kennzahlen
| CUSIP | – |
|---|---|
| ISIN | – |
| Typ | Common Stock |
| Marktkapitalisierung | 2,91 Mrd. USD |
| Beta | 1,29 |
| Dividendenrendite | 0,00 % |
Externe Quellen: SEC EDGAR » · FMP-Profil » · Yahoo Finance »
Finanzkennzahlen (SEC XBRL)
| Periode | Filing | Umsatz | Nettoergebnis | EPS | Aktiva | Eigenkapital |
|---|---|---|---|---|---|---|
| 2025-12-31 | 10-K | -446,214,000 | -3.47 | 1,186,958,000 | 972,129,000 | |
| 2025-09-30 | 10-Q | -108,041,000 | -0.76 | 867,059,000 | 691,783,000 | |
| 2025-06-30 | 10-Q | -110,857,000 | -0.97 | 728,992,000 | 571,445,000 | |
| 2025-03-31 | 10-Q | -115,361,000 | -1.05 | 721,074,000 | 668,973,000 | |
| 2024-12-31 | 10-K | -317,418,000 | -3.37 | 691,234,000 | 629,838,000 | |
| 2024-09-30 | 10-Q | -97,125,000 | -0.96 | 768,844,000 | 705,540,000 | |
| 2024-06-30 | 10-Q | -65,102,000 | -0.70 | 825,884,000 | 775,193,000 | |
| 2024-03-31 | 10-Q | -65,649,000 | -0.81 | 522,279,000 | 478,055,000 | |
| 2023-12-31 | 10-K | -235,937,000 | -3.95 | 165,082,000 | 91,292,000 | |
| 2023-09-30 | 10-Q | -60,210,000 | -0.99 | 205,244,000 | 152,038,000 | |
| 2023-06-30 | 10-Q | -64,902,000 | -1.08 | 251,421,000 | 206,877,000 | |
| 2023-03-31 | 10-Q | -44,187,000 | -0.78 | 288,642,000 | 241,935,000 | |
| 2022-12-31 | 10-K | -168,099,000 | -3.23 | 306,325,000 | 252,364,000 | |
| 2022-09-30 | 10-Q | -41,385,000 | -0.80 | 299,679,000 | 249,744,000 | |
| 2022-06-30 | 10-Q | -52,304,000 | -1.01 | 340,026,000 | 287,059,000 | |
| 2022-03-31 | 10-Q | -35,583,000 | -0.69 | 387,762,000 | 336,459,000 | |
| 2021-12-31 | 10-K | -149,291,000 | -2.93 | 425,663,000 | 368,197,000 | |
| 2021-09-30 | 10-Q | -42,582,000 | -0.83 | 466,878,000 | 414,116,000 | |
| 2021-06-30 | 10-Q | -29,955,000 | -0.58 | 467,147,000 | 452,596,000 | |
| 2021-03-31 | 10-Q | -24,968,000 | 491,710,000 | 478,260,000 |
Fondsaktivität (Vorquartalsvergleich)
Keine Fondsdaten für dieses Unternehmen vorhanden.
Insider-Transaktionen (12 Monate)
| Datum | Insider | Rolle | Typ | Stückzahl | Kurs | Wert (USD) | Δ | Trend |
|---|---|---|---|---|---|---|---|---|
| 2026-04-27 | Rhodes Jason P | Director | Open Market Sale | -45,709 | 18.15 | -829,618.35 | -93,7% | |
| 2026-04-27 | Rhodes Jason P | Director | Open Market Sale | -35,947 | 18.15 | -652,438.05 | -73,7% | |
| 2026-04-27 | Rhodes Jason P | Director | Open Market Sale | -894 | 18.15 | -16,226.10 | -1,8% | |
| 2026-04-27 | Rhodes Jason P | Director | Open Market Sale | -90,943 | 18.15 | -1,650,615.45 | -186,4% | |
| 2026-04-24 | Rhodes Jason P | Director | Open Market Sale | -710 | 18.48 | -13,120.80 | -1,5% | |
| 2026-04-24 | Rhodes Jason P | Director | Open Market Sale | -36,345 | 18.48 | -671,655.60 | -75,9% | |
| 2026-04-24 | Rhodes Jason P | Director | Open Market Sale | -72,310 | 18.48 | -1,336,288.80 | -150,9% | |
| 2026-04-24 | Rhodes Jason P | Director | Open Market Sale | -28,583 | 18.48 | -528,213.84 | -59,7% | |
| 2026-04-23 | Rhodes Jason P | Director | Open Market Sale | -15,148 | 19.19 | -290,690.12 | -32,8% | |
| 2026-04-23 | Rhodes Jason P | Director | Open Market Sale | -38,322 | 19.19 | -735,399.18 | -83,1% | |
| 2026-04-23 | Rhodes Jason P | Director | Open Market Sale | -19,261 | 19.19 | -369,618.59 | -41,7% | |
| 2026-04-23 | Rhodes Jason P | Director | Open Market Sale | -377 | 19.19 | -7,234.63 | -0,8% | |
| 2026-04-22 | Rhodes Jason P | Director | Open Market Sale | -75,866 | 19.68 | -1,493,042.88 | -168,6% | |
| 2026-04-22 | Rhodes Jason P | Director | Open Market Sale | -1,485 | 19.68 | -29,224.80 | -3,3% | |
| 2026-04-22 | Kersten Dirk | Director | Open Market Sale | -2,652 | 20.00 | -53,049.28 | -6,0% | |
| 2026-04-22 | Rhodes Jason P | Director | Open Market Sale | -150,942 | 19.68 | -2,970,538.56 | -335,5% | |
| 2026-04-22 | Rhodes Jason P | Director | Open Market Sale | -59,663 | 19.68 | -1,174,167.84 | -132,6% | |
| 2026-04-21 | Rhodes Jason P | Director | Open Market Sale | -769 | 20.05 | -15,418.45 | -1,7% | |
| 2026-04-21 | Kersten Dirk | Director | Open Market Sale | -8,300 | 20.01 | -166,120.35 | -18,8% | |
| 2026-04-21 | Rhodes Jason P | Director | Open Market Sale | -142,253 | 19.51 | -2,775,356.03 | -313,5% | |
| 2026-04-21 | Rhodes Jason P | Director | Open Market Sale | -71,499 | 19.51 | -1,394,945.49 | -157,6% | |
| 2026-04-21 | Rhodes Jason P | Director | Open Market Sale | -56,228 | 19.51 | -1,097,008.28 | -123,9% | |
| 2026-04-21 | Rhodes Jason P | Director | Open Market Sale | -1,530 | 20.05 | -30,676.50 | -3,5% | |
| 2026-04-21 | Rhodes Jason P | Director | Open Market Sale | -1,398 | 19.51 | -27,274.98 | -3,1% | |
| 2026-04-21 | Rhodes Jason P | Director | Open Market Sale | -605 | 20.05 | -12,130.25 | -1,4% | |
| 2026-04-21 | Rhodes Jason P | Director | Open Market Sale | -15 | 20.05 | -300.75 | 0,0% | |
| 2026-04-20 | Rhodes Jason P | Director | Open Market Sale | -71,676 | 20.06 | -1,437,820.56 | -162,4% | |
| 2026-04-20 | Kersten Dirk | Director | Open Market Sale | -125,274 | 20.07 | -2,513,898.41 | -283,9% | |
| 2026-04-20 | Rhodes Jason P | Director | Open Market Sale | -1,401 | 20.06 | -28,104.06 | -3,2% | |
| 2026-04-20 | Rhodes Jason P | Director | Open Market Sale | -56,368 | 20.06 | -1,130,742.08 | -127,7% | |
| 2026-04-20 | Rhodes Jason P | Director | Open Market Sale | -142,604 | 20.06 | -2,860,636.24 | -323,1% | |
| 2026-04-17 | Kersten Dirk | Director | Open Market Sale | -211,974 | 20.29 | -4,301,291.62 | -485,8% | |
| 2026-04-16 | Kersten Dirk | Director | Open Market Sale | -11,116 | 21.10 | -234,590.95 | -26,5% | |
| 2026-04-16 | Kersten Dirk | Director | Open Market Sale | -6,657 | 20.06 | -133,522.78 | -15,1% | |
| 2026-04-15 | Kersten Dirk | Director | Open Market Sale | -81,840 | 20.27 | -1,659,044.11 | -187,4% | |
| 2026-03-30 | Posner Brian S | Director | Open Market Purchase | 2,000 | 17.08 | 34,160.00 | +3,9% | |
| 2026-03-11 | Kersten Dirk | Director | Open Market Sale | -129,672 | 19.52 | -2,530,562.05 | -285,8% | |
| 2026-03-10 | Kersten Dirk | Director | Open Market Sale | -9,482 | 18.21 | -172,687.13 | -19,5% | |
| 2026-03-10 | Kersten Dirk | Director | Open Market Sale | -281,858 | 19.80 | -5,580,816.59 | -630,3% | |
| 2026-03-10 | Kersten Dirk | Director | Open Market Sale | -219,758 | 19.33 | -4,246,823.35 | -479,7% | |
| 2026-03-09 | Kersten Dirk | Director | Open Market Sale | -177,690 | 17.72 | -3,148,986.64 | -355,7% | |
| 2026-03-05 | Cox John | Director, Officer, CEO & President | Open Market Sale | -2,732 | 14.90 | -40,706.80 | -4,6% | |
| 2026-03-05 | Friedl-Naderer Johanna | Officer, Chief Commercial Officer | Open Market Sale | -148 | 14.90 | -2,205.20 | -0,2% | |
| 2026-03-05 | Kerr Douglas | Officer, Chief Medical Officer | Open Market Sale | -904 | 14.90 | -13,469.60 | -1,5% | |
| 2025-12-05 | Friedl-Naderer Johanna | Officer, Chief Commercial Officer | Open Market Sale | -144 | 20.72 | -2,983.68 | -0,3% | |
| 2025-12-05 | Cox John | Director, Officer, CEO & President | Open Market Sale | -2,662 | 20.72 | -55,156.64 | -6,2% | |
| 2025-12-05 | Kerr Douglas | Officer, Chief Medical Officer | Open Market Sale | -880 | 20.72 | -18,233.60 | -2,1% | |
| 2025-09-05 | Friedl-Naderer Johanna | Officer, Chief Commercial Officer | Open Market Sale | -144 | 13.41 | -1,931.04 | -0,2% | |
| 2025-09-05 | Cox John | Director, Officer, CEO & President | Open Market Sale | -2,640 | 13.41 | -35,402.40 | -4,0% | |
| 2025-09-05 | Kerr Douglas | Officer, Chief Medical Officer | Open Market Sale | -873 | 13.41 | -11,706.93 | -1,3% | |
| 2025-09-04 | Kerr Douglas | Officer, Chief Medical Officer | Open Market Sale | -3,552 | 13.27 | -47,135.04 | -5,3% | |
| 2025-09-04 | Friedl-Naderer Johanna | Officer, Chief Commercial Officer | Open Market Sale | -894 | 13.27 | -11,863.38 | -1,3% | |
| 2025-07-14 | Cox John | Director, Officer, CEO & President | Open Market Purchase | 100,000 | 9.11 | 911,000.00 | +102,9% | |
| 2025-06-05 | Friedl-Naderer Johanna | Officer, Chief Commercial Officer | Open Market Sale | -146 | 13.35 | -1,949.10 | -0,2% | |
| 2025-06-05 | Cox John | Director, Officer, CEO & President | Open Market Sale | -4,060 | 13.35 | -54,201.00 | -6,1% | |
| 2025-06-05 | Kerr Douglas | Officer, Chief Medical Officer | Open Market Sale | -1,342 | 13.35 | -17,915.70 | -2,0% |
Top-Fondshalter
Keine Fondsdaten zu dieser Aktie vorhanden.